Evidence-based medical perspectives: the evolving role of PSA for early detection, monitoring of treatment response, and as a surrogate end point of efficacy for interventions in men with different clinical risk states for the prevention and progression of prostate cancer.

American journal of therapeutics

Volumn 11, Issue 6, 2004, Pages 501-506

  Lieberman, Ronald ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

BONE TUMOR; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; EVIDENCE BASED MEDICINE; HUMAN; MALE; METASTASIS; MIDDLE AGED; PATHOLOGY; PROSTATE TUMOR; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK ASSESSMENT;

BONE NEOPLASMS; EVIDENCE-BASED MEDICINE; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT; TUMOR MARKERS, BIOLOGICAL;

EID: 14844353070     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mjt.0000141604.20320.0c     Document Type: Review

References (29)